New drug policy perplexes GSK

Published: 2008-02-25 07:00:00

Updated: 2008-02-25 07:00:00

As the government decided to exclude Tykerb (lapatinib) from the list of national health insurance last month, GlaxoSmithKline is in dilemma to launch the product, saying it would limit Korean patients' access to newly-developed drugs.

The Health Insurance Review & Assessment Service said Tyke...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK